论文部分内容阅读
目的观察小剂量尿激酶(UK)联合低分子肝素钙治疗进展性脑梗死的临床疗效及安全性。方法选取发病6 h后症状仍旧没有得到改善的40例急性脑梗死患者作为研究对象,随机分为对照组(接受常规治疗)、观察组(在常规治疗基础上应用小剂量尿激酶联合低分子肝素钙)。比较2组临床疗效以及不良反应发生情况。结果观察组总有效显著高于对照组(P<0.05);观察组有2例患者发生局部皮下瘀血,没有给治疗带来不利影响,无严重出血性并发症发生。结论在常规治疗基础上应用小剂量尿激酶联合低分子肝素钙治疗进展性脑梗死,不仅疗效显著,而且具有较高的安全系数。
Objective To observe the clinical efficacy and safety of low-dose urokinase (UK) and low-molecular-weight heparin in the treatment of patients with progressive cerebral infarction. Methods Forty acute cerebral infarction patients whose symptom still did not improve after 6 h were selected as the research object and randomly divided into control group (receiving routine treatment) and observation group (on the basis of routine treatment, low-dose urokinase combined with low-molecular-weight heparin calcium). The clinical efficacy and the incidence of adverse reactions in the two groups were compared. Results The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). Local subcutaneous bleeding was observed in 2 patients in the observation group, without adverse effects on the treatment and without severe hemorrhagic complications. Conclusion In the conventional treatment based on the application of low-dose urokinase combined with low molecular weight heparin calcium in patients with progressive cerebral infarction, not only significant effect, but also has a high safety factor.